Utility of Identifying Obesity Associated Methylation Changes in AML (Acute Myeloid Leukemia) Patients: Correlation With Clinical Outcome and Drug Response

被引:0
|
作者
Kolhe, Ravindra B.
Deremer, David
Rojiani, Amyn
Mondal, Ashis
Mangaonkar, Bhishek
Kota, Vamsi
机构
[1] Georgia Regents Univ, Augusta, GA USA
[2] Emory Univ, Atlanta, GA 30322 USA
关键词
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1421
引用
收藏
页码:356A / 356A
页数:1
相关论文
共 50 条
  • [41] Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
    Chretien, Anne-Sophie
    Fauriat, Cyril
    Orlanducci, Florence
    Galseran, Claire
    Rey, Jerome
    Borg, Gaelle Bouvier
    Gautherot, Emmanuel
    Granjeaud, Samuel
    Hamel-Broza, Jean-Francois
    Demerle, Clemence
    Ifrah, Norbert
    Lacombe, Catherine
    Cornillet-Lefebvre, Pascale
    Delaunay, Jacques
    Toubert, Antoine
    Gregori, Emilie
    Luche, Herve
    Malissen, Marie
    Arnoulet, Christine
    Nunes, Jacques A.
    Vey, Norbert
    Olive, Daniel
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [42] OVEREXPRESSION OF ENHANCER OF ZESTE HOMOLOG 2 IS ASSOCIATED WITH CLINICAL OUTCOME IN ACUTE MYELOID LEUKEMIA PATIENTS
    Lin, P.
    Yeh, S.
    Bai, L.
    Lin, C.
    Chiu, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 349 - 349
  • [43] COMPARISON OF SECONADRY ACUTE MYELOID LEUKEMIA WITH DE NOVO AML: CLINICAL FEATURES AND TREATMENT OUTCOME
    Choi, Y. S.
    Lee, J. H.
    Kim, D. Y.
    Lee, J. H.
    Kim, S. H.
    Lim, S. N.
    Kim, S. D.
    Seol, M.
    Kang, S. I.
    Lee, K. H.
    Kim, J. Y.
    Lee, Y. S.
    Kang, Y. A.
    Ryu, S. G.
    Lee, K. Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 548 - 548
  • [44] Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia
    Quartino, Angelica
    Karlsson, Mats O.
    Freijs, Agneta
    Jonsson, Niclas
    Nygren, Peter
    Kristensen, Jorgen
    Lindhagen, Elin
    Larsson, Rolf
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (08): : 1014 - 1021
  • [45] Acute myeloid leukemia (AML) M0: Clinical characteristics and outcome. An analysis in 263 patients.
    Bene, MC
    Bernier, M
    Casasnovas, RO
    Castoldi, G
    Doekharan, D
    van der Holt, B
    Knapp, W
    Lemez, P
    Ludwig, WD
    Matures, E
    Orfao, A
    Schoch, C
    Sterling, C
    van 't Veer, MB
    BLOOD, 1999, 94 (10) : 67A - 67A
  • [46] Clinical profile and outcome of patients of acute myeloid leukemia with high hyperdiploidy
    Sharma, Sanjeev Kumar
    Sharma, Monica
    Seth, Tulika
    Mishra, Pravas
    Chowdhry, Mohit
    Mahapatra, Manoranjan
    Saxena, Renu
    LEUKEMIA RESEARCH, 2012, 36 (03) : E60 - E61
  • [47] RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)
    Gaidzik, Verena I.
    Schlenk, Richard F.
    Wittke, Kerstin
    Becker, Annegret
    Zimmermann, Andreas
    Schlegelberger, Brigitte
    Ganser, Arnold
    Spaeth, Daniela
    Doehner, Hartmut
    Doehner, Konstanze
    BLOOD, 2008, 112 (11) : 59 - 59
  • [48] Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients
    Achille, Nicholas J.
    Othus, Megan
    Phelan, Kathleen
    Zhang, Shubin
    Cooper, Kathrine
    Godwin, John E.
    Appelbaum, Frederick R.
    Radich, Jerald P.
    Erba, Harry P.
    Nand, Sucha
    Zeleznik-Le, Nancy J.
    LEUKEMIA RESEARCH, 2016, 42 : 68 - 74
  • [49] HIF2A is Associated with Improved Survival in Acute Myeloid Leukemia (AML) Patients
    Lee, Kian Leong
    Iqbal, Jabed
    Wong, Gee Chuan
    Ong, Sin Tiong
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1180 - S1181
  • [50] Exclusion from acute myeloid leukemia (AML) clinical trials of patients unlikely to respond
    Tsimberidou, Apostolia-Maria
    Kantarjian, Hagop M.
    Faderl, Stefan
    Freireich, Emil J.
    Estey, Elihu
    BLOOD, 2007, 110 (11) : 843A - 843A